The Ocular Surface Characteristics in Prostate Cancer Patients Treated with Androgen Deprivation Therapy

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Background.To investigate the association of long-term androgen deprivation therapy (ADT) with ocular surface characteristics in prostate cancer patients. Methods. A total of 30 male prostate cancer patients who received ADT were selected. All candidates were scored using the Ocular Surface Disease Index (OSDI) and subsequently divided into two groups containing 9 symptomatic patients (scores >12) and 21 asymptomatic patients ( ). Another 20 healthy age-matched males were selected as the control group. Each candidate was assessed with respect to eyelid margin abnormality, tear film break-up time (NI-BUT), tear meniscus height (TMH), meiboscore, meibum expressibility, and demodex infection. Results. The NI-BUT in the ADT group was significantly shorter than that in the control group. The scores for OSDI, eyelid margin abnormality, meibum expressibility, and meiboscores were significantly higher in the ADT group ( ). Moreover, the NI-BUT in the symptomatic ADT group was significantly shorter than that in the asymptomatic ADT group ( ). The meiboscores and meibum expressibility score in the symptomatic ADT group were significantly higher than those in the asymptomatic ADT group ( ). The presence of demodex in the symptomatic ADT group was also higher than that in the asymptomatic ADT group ( ). The length of time that patients had been taking ADT was positively correlated with meiboscores and negatively correlated with NI-BUT. Conclusion. Androgen levels were associated with significant changes in relative meibomian gland function. Subjective symptoms, such as dryness and foreign body sensation, were more obvious in prostate cancer patients receiving ADT, which may be caused by MGD and demodex infection. It’s recommended that more attention be paid to the ocular surface in prostate cancer patients taking ADT by performing examination of NI-BUT and meibomian gland morphology and function with a view to providing more comprehensive prevention and treatment protocols.
Funding Information
  • Huaxia Translational Medicine Fund for Young Scholars (2017-A-002, 2017-A-001, SH2019033, 3502Z20191101, 2016-ZQN-90, 81672955, 81770891, 82070931, 81970771, 2020YFA0908100)
  • Zhenjiang Science Technology Planning Project (2017-A-002, 2017-A-001, SH2019033, 3502Z20191101, 2016-ZQN-90, 81672955, 81770891, 82070931, 81970771, 2020YFA0908100)
  • Xiamen key medical and health project (2017-A-002, 2017-A-001, SH2019033, 3502Z20191101, 2016-ZQN-90, 81672955, 81770891, 82070931, 81970771, 2020YFA0908100)
  • Health Research Talent Training Program of Fujian PRC (2017-A-002, 2017-A-001, SH2019033, 3502Z20191101, 2016-ZQN-90, 81672955, 81770891, 82070931, 81970771, 2020YFA0908100)
  • National Natural Science Foundation of China (2017-A-002, 2017-A-001, SH2019033, 3502Z20191101, 2016-ZQN-90, 81672955, 81770891, 82070931, 81970771, 2020YFA0908100)
  • National Key R&D Program of China (2017-A-002, 2017-A-001, SH2019033, 3502Z20191101, 2016-ZQN-90, 81672955, 81770891, 82070931, 81970771, 2020YFA0908100)

This publication has 30 references indexed in Scilit: